Mol Cell Biol. 1991 January; 11(1): 12-19
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
J Milner,
E A Medcalf and
A C Cook
Department of Pathology, University of Cambridge, United Kingdom.
ABSTRACT
It has been suggested that the dominant effect of mutant p53 on tumor progression may reflect the mutant protein binding to wild-type p53, with inactivation of suppressor function. To date, evidence for wild-type/mutant p53 complexes involves p53 from different species. To investigate wild-type/mutant p53 complexes in relation to natural tumor progression, we sought to identify intraspecific complexes, using murine p53. The mutant phenotype p53-246(0) was used because this phenotype is immunologically distinct from wild-type p53-246+ and thus permits immunological analysis for wild-type/mutant p53 complexes. The p53 proteins were derived from genetically defined p53 cDNAs expressed in vitro and also from phenotypic variants of p53 expressed in vivo. We found that the mutant p53 phenotype was able to form a complex with the wild type when the two p53 variants were cotranslated. When mixed in their native states (after translation), the wild-type and mutant p53 proteins did not exhibit any binding affinity for each other in vitro. Under identical conditions, complexes of wild-type human and murine p53 proteins were formed. For murine p53, both the wild-type and mutant p53 proteins formed high-molecular-weight complexes when translated in vitro. This oligomerization appeared to involve the carboxyl terminus, since truncated p53 (amino acids 1 to 343) did not form complexes. We suggest that the ability of the mutant p53 phenotype to complex with wild type during cotranslation may contribute to the transforming function of activated mutants of p53 in vivo.
Mol Cell Biol. 1991 January; 11(1): 12-19
This article has been cited by other articles:
-
Kalo, E., Buganim, Y., Shapira, K. E., Besserglick, H., Goldfinger, N., Weisz, L., Stambolsky, P., Henis, Y. I., Rotter, V.
(2007). Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor {beta}1 (TGF-{beta}1) Signaling Pathway by Repressing the Expression of TGF-{beta} Receptor Type II. Mol. Cell. Biol.
27: 8228-8242
[Abstract]
[Full Text]
-
Wijnhoven, S. W.P., Speksnijder, E. N., Liu, X., Zwart, E., vanOostrom, C. Th. M., Beems, R. B., Hoogervorst, E. M., Schaap, M. M., Attardi, L. D., Jacks, T., van Steeg, H., Jonkers, J., de Vries, A.
(2007). Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage. Cancer Res.
67: 4648-4656
[Abstract]
[Full Text]
-
Mills, A. A.
(2005). p53: link to the past, bridge to the future. Genes Dev.
19: 2091-2099
[Full Text]
-
De Laurenzi, V., Raschella, G., Barcaroli, D., Annicchiarico-Petruzzelli, M., Ranalli, M., Catani, M. V., Tanno, B., Costanzo, A., Levrero, M., Melino, G.
(2000). Induction of Neuronal Differentiation by p73 in a Neuroblastoma Cell Line. J. Biol. Chem.
275: 15226-15231
[Abstract]
[Full Text]
-
Okorokov, A. L., Milner, J.
(1999). An ATP/ADP-Dependent Molecular Switch Regulates the Stability of p53-DNA Complexes. Mol. Cell. Biol.
19: 7501-7510
[Abstract]
[Full Text]
-
Di Como, C. J., Gaiddon, C., Prives, C.
(1999). p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells. Mol. Cell. Biol.
19: 1438-1449
[Abstract]
[Full Text]
-
Robbins, P.
(1996). p53 and Breast Cancer. INT J SURG PATHOL
4: 93-110
[Abstract]
-
Bowman, T, Symonds, H, Gu, L, Yin, C, Oren, M, Van Dyke, T
(1996). Tissue-specific inactivation of p53 tumor suppression in the mouse.. Genes Dev.
10: 826-835
[Abstract]
-
Bargonetti, J, Reynisdottir, I, Friedman, P N, Prives, C
(1992). Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.. Genes Dev.
6: 1886-1898
[Abstract]
-
Weinberg, R.
(1991). Tumor suppressor genes. Science
254: 1138-1146
[Abstract]
-
Akakura, S., Yoshida, M., Yoneda, Y., Horinouchi, S.
(2001). A Role for Hsc70 in Regulating Nucleocytoplasmic Transport of a Temperature-sensitive p53 (p53Val-135). J. Biol. Chem.
276: 14649-14657
[Abstract]
[Full Text]
-
de Vries, A., Flores, E. R., Miranda, B., Hsieh, H.-M., van Oostrom, C. Th. M., Sage, J., Jacks, T.
(2002). Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA
99: 2948-2953
[Abstract]
[Full Text]
Copyright © 1991 by the American Society for Microbiology. All rights reserved.